Vyera Pharmaceuticals, LLC
600 Third Avenue, 10th Floor
About Vyera Pharmaceuticals, LLC
Vyera Pharmaceuticals is focused on developing therapies specifically targeted to treat patients suffering from serious and neglected diseases with high unmet needs. One of Vyera’s areas of focus is toxoplasmosis.
3 articles with Vyera Pharmaceuticals, LLC
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis
Vyera Pharmaceuticals, LLC announced it plans to initiate a Phase 1 single ascending dose (SAD) study of VYR-006, a novel dihydrofolate reductase (DHFR) inhibitor which Vyera discovered and is developing for the treatment of toxoplasmosis.
Vyera Pharma Has Initiated a Phase I Study of a New Dihydrofolate Reductase Inhibitor Designed as a Potential Treatment for Toxoplasmosis
Vyera Pharma announced the initiation of a Phase 1 single ascending dose study of TUR-006.